-
Mashup Score: 1Short-term dose and duration-dependent glucocorticoid risk for cardiovascular events in glucocorticoid-naive patients with rheumatoid arthritis - 3 year(s) ago
Objectives Rheumatoid arthritis (RA), along with glucocorticoid use, is associated with cardiovascular disease. Cardiovascular safety of glucocorticoids in RA is controversial and may be related to dose and duration of use. We determined if initiating glucocorticoids in steroid-naive RA patients would increase cardiovascular event (CVE) risk in a dose and duration-dependent manner over short-term…
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet
-
Mashup Score: 2
Objectives To evaluate the success rate of glucocorticoid discontinuation and to study which factors are associated with successful discontinuation. Methods Data from two treat-to-target studies, BeSt (target Disease Activity Score (DAS) ≤2.4) and IMPROVED (target DAS <1.6), were evaluated for all patients initially treated with a tapered high dose of prednisone with conventional synthetic...
Source: Annals of the Rheumatic DiseasesCategories: Latest Headlines, RheumatologyTweet-
⭐️Live from #ACR21 Review Course Dr. Bryant England's RA session 📌Multiple EB approaches to GC tapering 📌 predictors of success= male sex, ⬇️ DAS Refs: 🔹https://t.co/RXjB9ujq7W 🔹https://t.co/zN4N8DqQlV 🔹https://t.co/Juph2vXHcv #ACRambassador https://t.co/fySiOeVhZO
-
-
Mashup Score: 8Myositis‐specific autoantibodies: an important tool to support diagnosis of myositis - 3 year(s) ago
Content List – Read more articles from the symposium: The First International Conference on Myositis.
Source: Wiley Online LibraryCategories: Latest Headlines, RheumatologyTweet-
📌 #ACR21 Review on Myositis by @docrota Love this graphic for AutoAb phenotypes Full ref here: https://t.co/0wRzXwCzib #ACRambassador https://t.co/uu9AV1XbxP
-
-
Mashup Score: 2ACR Convergence 2021 - 3 year(s) ago
ACR Convergence is the world’s premier virtual rheumatology experience where rheumatology can collaborate, celebrate, innovate, & learn. Join us online November 5 – 9.
Source: meet.acrconvergence.orgCategories: Latest Headlines, RheumatologyTweet-
A who’s who of SLE featuring Peggy Crow (who had one of the best lupus talks I have ever seen this morning at #ACR21) and Thomas Dörner in this session’s Community Hub #SLE. Come join the discussion!! #ACRAmbassador https://t.co/3X35mtu2ku
-
-
Mashup Score: 6
Original Article from The New England Journal of Medicine — Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Source: New England Journal of MedicineCategories: Healthcare Professionals, Latest HeadlinesTweet-
RT @EBRheum: #ACR21 #ACRAmbassador Fascinating analysis of rheum dx from the (negative!) VITAL study (https://t.co/aMtMCIf1F1) Very few…
-
-
Mashup Score: 16
Original Article from The New England Journal of Medicine — Vitamin D Supplements and Prevention of Cancer and Cardiovascular Disease
Source: New England Journal of MedicineCategories: Latest Headlines, RheumatologyTweet-
#ACR21 #ACRAmbassador Fascinating analysis of rheum dx from the (negative!) VITAL study (https://t.co/aMtMCIf1F1) Very few pts 278/25,871 (1.1%) but HR 0.78, p = 0.045 for vitamin D preventing autoimmune disease Do you believe it? If so, what's your public policy advice? https://t.co/ZkO5nHAJz9
-
-
Mashup Score: 6ACR Convergence 2021 - 3 year(s) ago
ACR Convergence is the world’s premier virtual rheumatology experience where rheumatology can collaborate, celebrate, innovate, & learn. Join us online November 5 – 9.
Source: meet.acrconvergence.orgCategories: Latest Headlines, RheumatologyTweet-
Please join me today at 1400 EST to hear Dr. Jane Salmon from @HSpecialSurgery discuss the rapidly emerging field of complement therapeutics, and how this could impact rheumatic diseases. Hope to you then! #ACR21 #ACRAmbassador https://t.co/uZNLrybkFG
-
-
Mashup Score: 2ACR Convergence 2021 - 3 year(s) ago
ACR Convergence is the world’s premier virtual rheumatology experience where rheumatology can collaborate, celebrate, innovate, & learn. Join us online November 5 – 9.
Source: meet.acrconvergence.orgCategories: Latest Headlines, RheumatologyTweet-
Happening now at #ACR21 - come check out the abstracts focusing on healthcare disparities in rheumatology! @LLUHealth rheumatology fellow Dr. Ehizogie Edigin discusses his work on hospitalizations in #SLE flares. @ACRheum #ACRambassador https://t.co/c0PDbqhASF https://t.co/02CQCF2ZZP
-
-
Mashup Score: 3Sign in - Google Accounts - 3 year(s) ago
AfrikaansazərbaycanbosanskicatalàČeštinaDanskDeutscheestiEnglish (United Kingdom)English (United States)Español (España)Español (Latinoamérica)FilipinoFrançais (Canada)Français (France)galegoHrvatskiIndonesiaisiZuluíslenskaItalianoKiswahililatviešulietuviųmagyarMelayuNederlandsnorskpolskiPortuguês (Brasil)Português…
Source: accounts.google.comCategories: Latest Headlines, RheumatologyTweet-
#ACR21 #vasculitis: Looking forward some great talks & the first community hub! Please enter some difficult and challenging cases! https://t.co/S4d4ndyOld. Should make for a fun meeting on Tuesday #ACRambassador @AMollaeianMD https://t.co/KhjwjDD7DG
-
-
Mashup Score: 0
NCT00204022.
Source: PubMedCategories: Latest Headlines, RheumatologyTweet-
Great question @MaxKonigMD. No doubt @AuriniaPharma will look at this in the future. BUT, clinical outcomes much better when UPCR < 0.7 1 yr following treatment. So maybe proteinuria OK? For now? https://t.co/iGZdVviAdG #ACR21 #ACRAmbassador https://t.co/69CJva2Xit
-
⭐️ Live from #ACR21 Review Course Dr. Bryant England's RA session Increasing data on adverse effects/toxicity of GC exposure even with pred doses < 10mg/day (👀 HR ⬆️in lower left) Ref: https://t.co/tXxFIaqsXJ #ACRambassador https://t.co/pLX83tu9YX